Abstract
Sixty-nine patients with Parkinson's disease were randomly allocated in a trial to compare the therapeutic effects of levodopa and amantadine. The patients were assessed clinically and scored by occupational therapy tasks and degrees of disability. Both drugs were used for 2 months; in the first 4 weeks the doses were gradually increased to 400 mg of amantadine or 4 g of levodopa respectively, and in the second 4 weeks' period the maximum tolerated dose was maintained throughout. Fourteen patients withdrew and these were excluded from the series. Of the fifty-five patients who completed the trial, thirty-four were taking levodopa and twenty-one amantadine.
The results showed an average 33% improvement on levodopa and 23% on amantadine as regards tremor, rigidity and akinesia and their total scores improved 26% and 18% respectively. More cases showed substantial improvement on levodopa.
There was little difference in response between 200 and 400 mg amantadine daily, but side-effects with 400 mg amantadine daily were more frequent and severe. Side-effects with levodopa were similar to those reported in previous trials but we also noted brown body fluids in three patients. The average effective dose of levodopa was lower than in previous reports, and the largest number of patients received benefit from 1·5 g daily. The superior effect of levodopa was shown.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Dallos V., Heathfield K., Stone P., Allen F. A. Use of amantadine in Parkinson's disease. Results of a double-blind trial. Br Med J. 1970 Oct 3;4(5726):24–26. doi: 10.1136/bmj.4.5726.24. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fieschi C., Nardini M., Casacchia M., Tedone M. E., Reitano M., Robotti E. Amantadine versus L-2 dopa and amatadine plus L-dopa. Lancet. 1970 Jul 18;2(7664):154–155. doi: 10.1016/s0140-6736(70)92742-x. [DOI] [PubMed] [Google Scholar]
- Godwin-Austen R. B., Frears C. C., Bergmann S. Incidence of side effects from levodopa during the introduction of treatment. Br Med J. 1971 Jan 30;1(5743):267–268. doi: 10.1136/bmj.1.5743.267. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hughes R. C., Polgar J. G., Weightman D., Walton J. N. L-dopa in Parkinsonism and the influence of previous thalamotomy. Br Med J. 1971 Jan 2;1(5739):7–13. doi: 10.1136/bmj.1.5739.7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Humbert J. A., Hammond K. B., Hathaway W. E. Trimethylaminuria: the fish-odour syndrome. Lancet. 1970 Oct 10;2(7676):770–771. doi: 10.1016/s0140-6736(70)90241-2. [DOI] [PubMed] [Google Scholar]
- Hunter K. R., Stern G. M., Laurence D. R., Armitage P. Amantadine in parkinsonism. Lancet. 1970 May 30;1(7657):1127–1129. doi: 10.1016/s0140-6736(70)91210-9. [DOI] [PubMed] [Google Scholar]
- Parkes J. D., Zilkha K. J., Marsden P., Baxter R. C., Knill-Jones R. P. Amantadine dosage in treatment of Parkinson's disease. Lancet. 1970 May 30;1(7657):1130–1133. doi: 10.1016/s0140-6736(70)91211-0. [DOI] [PubMed] [Google Scholar]
- Rao N. S., Pearce J. Amantadine in Parkinsonism. An extended prospective trial. Practitioner. 1971 Feb;206(232):241–245. [PubMed] [Google Scholar]
- Schwab R. S., England A. C., Jr, Poskanzer D. C., Young R. R. Amantadine in the treatment of Parkinson's disease. JAMA. 1969 May 19;208(7):1168–1170. [PubMed] [Google Scholar]